mTOR inhibitors: all 1,276 studies that test it

Page 7 of 13. Open to participants first (126), then studies with results posted, then the rest; newest registration first within each.

• A Study of Sirolimus for Injection (Albumin-bound) in Patients With Advanced Solid TumorsStatus unknownNCT05508620Phase 1
• ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast CancerCompletedNCT05501769Phase 1
• Precise Therapy for Refractory HER2 Positive Advanced Breast CancerStatus unknownNCT05429684Phase 3
• This Study Consists of Two Study Parts Conducted Under a Single IRB. Part I: Short Term ApoE-dependent Cerebral Blood Flow Response to Sirolimus in Cognitively Normal Adults Part II: Short Term ApoE-dependent Cerebral Blood Flow and Lung Perfusion Response to Sirolimus in Cognitively Normal AdultsActive, not recruitingNCT05386914Phase 1
• Daily Topical Rapamycin for VitiligoActive, not recruitingNCT05342519Phase 2
• A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML)CompletedNCT05252585Phase 4
• Study to Compare the Efficacy and Safety After Conversion to RaparoBell® or My-Rept® in Kidney Transplant PatientsActive, not recruitingNCT05193565Phase 4
• Rapid Sequencing of Approved Therapies in Patients With Metastatic or Unresectable Clear Cell Renal Cell CarcinomaCompletedNCT05188118Early Phase 1
• Everolimus Trial in Laryngotracheal StenosisCompletedNCT05153668Early Phase 1
• A Study of Sirolimus for Injection (Albumin Bound) in Patients With Advanced Solid TumorsStatus unknownNCT05125523Phase 1
• Anlotinib Plus Everolimus as First-line Treatment for Advanced Non Clear Cell Renal Cell CarcinomaStatus unknownNCT05124431Phase 2
• Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention StudyActive, not recruitingNCT05104983Phase 2
• Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted GraftActive, not recruitingNCT05088356Phase 1
• Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell CancerActive, not recruitingNCT05012371Phase 2
• Effect of Rapamycin to Improve Cardiac Function in Frail Older AdultsCompletedNCT04996719Phase 1
• Assessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID FibrosisActive, not recruitingNCT04948203Phase 2/3
• Sirolimus in Treatment of Proteinuric Flares of Lupus NephritisStatus unknownNCT04892212Phase 2/3
• Efficacy and Safety of CertiroBell® Tablet Plus Tacrolimus in Primary Living Donor Liver Transplant RecipientsStatus unknownNCT04867720Phase 4
• Belatacept With Early Steroid Withdrawal rATG and Everolimus in Renal Transplantation (BETTER Trial)Status unknownNCT04849533Phase 4
• Phase III Trial of Sirolimus in IBMActive, not recruitingNCT04789070Phase 3
• Efficacy and Safety of Different Concentrations of Sirolimus in the Treatment of Kaposiform Hemangioendothelioma.CompletedNCT04775173Phase 2
• Effect of mTOR Inhibition & Other Metabolism Modulating Interventions on the Elderly [SubStudy Rapa & cMRI to Evaluate Cardiac Function]Active, not recruitingNCT04742777Phase 2
• Sirolimus for Retinal Astrocytic HamartomaCompletedNCT04707209Not applicable
• Rapamycin - Effects on Alzheimer's and Cognitive HealthActive, not recruitingNCT04629495Phase 2
• Efficacy and Safety of Sirolimus in Active Systemic Lupus ErythematosusActive, not recruitingNCT04582136Phase 3
• The Efficacy of Everolimus With Reduced-dose Tacrolimus Versus Reduced-dose Tacrolimus and Leflunomide in Treatment of BK Virus Infection in Kidney Transplantation RecipientActive, not recruitingNCT04542733Not applicable
• Participatory Evaluation (of) Aging (With) Rapamycin (for) Longevity StudyCompletedNCT04488601Phase 2
• Effects of mTOR Inhibition With Sirolimus (RAPA) in Patients With COVID-19 to Moderate the Progression of ARDSWithdrawnNCT04482712Phase 1/2
• Haplo Peripheral Blood Sct In GVHD PreventionCompletedNCT04473911Phase 1
• Sirolimus Treatment for Newly Diagnosed Primary Acquired PRCACompletedNCT04470804Phase 4
• Efficacy and Safety of Sirolimus in COVID-19 InfectionStatus unknownNCT04461340Phase 2
• Guided Discontinuation Versus Maintenance Treatment of Sirolimus in Pediatric Patients With Kaposiform HemangioendotheliomaCompletedNCT04448873Phase 4
• Phase 1/2 Clinical Trial of PR001 in Infants With Type 2 Gaucher Disease (PROVIDE)Active, not recruitingNCT04411654Phase 1/2
• SCMC Trial on KHE With KMP (V.2020)Status unknownNCT04409691Phase 1
• An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC.Active, not recruitingNCT04395989Phase 2
• Sirolimus in COVID-19 Phase 1WithdrawnNCT04371640Phase 1
• Reduced Intensity Transplantation for Severe Sickle Cell DiseaseActive, not recruitingNCT04362293Phase 2
• Molecularly Targeted Umbrella Study in Luminal Advanced Breast CancerStatus unknownNCT04355858Phase 2
• Sirolimus Combined With ATRA for the Treatment of Auto-Immune AnemiaWithdrawnNCT04324411Phase 4
• Testing SIROLIMUS in Beta-thalassemia Transfusion Dependent Patients (THALA-RAP)Status unknownNCT04247750Phase 2
• A MolEcularly Guided Anti-Cancer Drug Off-Label TrialActive, not recruitingNCT04185831Phase 2
• TOPical Sirolimus in linGUal Microcystic Lymphatic Malformation -TOPGUNCompletedNCT04128722Phase 2
• Liposomal Sirolimus in Dry Eye DiseaseCompletedNCT04115800Early Phase 1
• Sirolimus for Cowden Syndrome With Colon PolyposisCompletedNCT04094675Phase 2
• Safety and Efficacy of Low-dose Sirolimus to Kaposiform HemangioendotheliomaCompletedNCT04077515Phase 4
• Study of Sirolimus in Idiopathic Retroperitoneal FibrosisCompletedNCT04047576Phase 2/3
• Treatment of Congenital Vascular Malformations Using Sirolimus: Improving Quality of LifeStatus unknownNCT03987152Phase 3
• NPC-12G Gel 0.2% Sirolimus PK Bridging StudyCompletedNCT03972462Phase 1
• Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid TumorsActive, not recruitingNCT03950609Phase 2
• The Efficacy and Safety of Sirolimus for Plastic BronchitisStatus unknownNCT03942926Phase 2
• Temsirolimus Alone or Paired With Dexamethasone Delivered to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal RevascularizationTerminatedNCT03942601Phase 2
• Adjunctive Sirolimus and Oseltamivir Versus Oseltamivir Alone for Treatment of InfluenzaActive, not recruitingNCT03901001Phase 3
• Testing SIROLIMUS in Beta-thalassemia Transfusion Dependent PatientsCompletedNCT03877809Phase 2
• Umbilical Cord Blood Transfusion in Progeria SyndromeCompletedNCT03871972Phase 1/2
• Sirolimus Combined With Low-dose Warfarin for the Treatment of Refractory PNHStatus unknownNCT03866681Phase 4
• RCT Comparing Immunosuppressive Regimens in Elderly Renal Transplant RecipientsActive, not recruitingNCT03797196Phase 4
• Efficacy of Rapamycin (Sirolimus) in the Treatment of Peutz-Jeghers SyndromeStatus unknownNCT03781050Phase 4
• Efficacy of Rapamycin (Sirolimus) in the Treatment of BRBNS, Hereditary or Sporadic Venous MalformationStatus unknownNCT03767660Phase 4
• Bioequivalence Study of NPC-12 (Sirolimus) Granules and TabletsCompletedNCT03765944Phase 1
• Study of Sirolimus in CTD-TP in ChinaStatus unknownNCT03688191Phase 4
• Study of Sirolimus in Patients With Advanced Pancreatic CancerStatus unknownNCT03662412Phase 1/2
• A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With GliomasWithdrawnNCT03632317Phase 2
• Treatment of Neuroendocrine Tumors (NETs) With Combination of Everolimus and Radiolabeled Somatostatin AnalogueStatus unknownNCT03629847Phase 1/2
• Efficacy and Safety of Sirolimus to Vascular AnomaliesCompletedNCT03583307Not applicable
• Sirolimus vs Mycophenolate With Tacrolimus in Simultaneous Pancreas and Kidney TransplantationCompletedNCT03582878Phase 4
• Everolimus in Castrated Resistant Prostate Cancer(CRPC)Patients With PI3K-AKT-mTOR Signaling Pathway DeficiencyStatus unknownNCT03580239Phase 3
• Everolimus in Restoring Salivary Gland Function in Participants With Locally Advanced Head and Neck Cancer Treated With Radiation TherapyTerminatedNCT03578432Early Phase 1
• Liver Transplantation With Tregs at MGHCompletedNCT03577431Phase 1/2
• Sirolimus-based Immunosuppression Treatment Regimen for Liver TransplantationStatus unknownNCT03500848Phase 2/3
• Efficacy and Safety of Rapamycin (Sirolimus) in the Treatment of Symptomatic Uterine Fibroids and LeiomyomatosisStatus unknownNCT03500367Phase 4
• Stem Cell Transplant in Patients With Severe Sickle Cell DiseaseTerminatedNCT03421756Early Phase 1
• Everolimus and Tacrolimus Combination for Regression of Left Ventricular Hypertrophy in Renal TransplantsCompletedNCT03415750Phase 4
• Rapamycin Treatment for Activated Phosphoinositide 3-Kinase δ SyndromeCompletedNCT03383380Phase 1/2
• Dose Finding Study to Determine if BEZ235 Alone or in Combination With RAD001 Decreases the Incidence of Respiratory Tract Infections in the ElderlyActive, not recruitingNCT03373903Phase 2
• A Pilot-Study of Sirolimus for the Treatment of Systemic SclerosisStatus unknownNCT03365869Phase 2
• Sirolimus Treatment for Refractory PRCACompletedNCT03364764Phase 4
• Rapamycin Treatment for ALSCompletedNCT03359538Phase 2
• A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)CompletedNCT03355794Phase 1
• Everolimus in Combination With Nelarabine, Cyclophosphamide and Etoposide in Lymphoblastic Leukemia/LymphomaCompletedNCT03328104Phase 1
• Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC)CompletedNCT03324373Phase 1
• Secondary Prevention Trial of Rapamycin in Patients With Resected Non-muscle Invasive Bladder CancerWithdrawnNCT03298958Phase 3
• Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene MutationCompletedNCT03285802Phase 2/3
• Twice-daily Tacrolimus and Everolimus Convert to Once-daily Tacrolimus and Everolimus in Liver Transplant RecipientCompletedNCT03256864Phase 4
• Multicenter Randomized Two-arms Study Evaluating the BK Viral Clearance in Kidney Transplant Recipients With BK Viremia.CompletedNCT03216967Phase 4
• A Study Investigating the Anti-epileptic Efficacy of Afinitor (Everolimus) in Patients With Refractory Seizures Who Have Focal Cortical Dysplasia Type II (FCD II)CompletedNCT03198949Phase 2
• Open-label Study on Treatment of Primary Aldosteronism With EverolimusCompletedNCT03174171Phase 2
• Immunomodulatory Effects of Rapamycin on Pregnancy Rate of Patient With Recurrent Implantation FailureCompletedNCT03161340Phase 2
• NCT Neuro Master Match - N²M² (NOA-20)CompletedNCT03158389Phase 1/2
• Multicenter Interventional Lymphangioleiomyomatosis (LAM) Early Disease TrialActive, not recruitingNCT03150914Phase 3
• Topical Rapamycin and Calcitriol for Angiofibroma of Tuberous SclerosisCompletedNCT03140449Phase 3
• UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib AloneSuspendedNCT03139747Phase 2
• Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)Active, not recruitingNCT03114527Phase 2
• Novel Compositions for Treating or Preventing Dermal DisordersCompletedNCT03103893Phase 1/2
• Phase 1 Study of the Effects of Combining Topical FDA-approved Drugs on Age-related Pathways on the Skin of Healthy VolunteersCompletedNCT03072485Phase 1
• Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS MutationTerminatedNCT03065387Phase 1
• Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) StudyStatus unknownNCT03016715Phase 2
• Fosbretabulin With Everolimus in Neuroendocrine Tumors With ProgressionTerminatedNCT03014297Phase 1
• A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial CarcinomaActive, not recruitingNCT03008408Phase 2
• Impact of Sirolimus and Maraviroc on CCR5 Expression and the HIV-1 Reservoir in HIV-infected Kidney Transplant RecipientsWithdrawnNCT02990312Phase 4
• Envarsus® Once Daily With Everolimus in Elderly Kidney Transplant Recipients: Pharmacokinetic and Clinical StudyCompletedNCT02970630Phase 2

← mTOR inhibitors overview